Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
Patients who do not meet the criteria but are funded by an individual funding request (IFR) will continue to receive funding via that route and do not need inclusion into Blueteq
This animation explains how to set up a new user account on Blueteq and what information is needed
Dr Simon Aylwin, King's College Hospital, Endocrinology CRG, explains the NHSE policy for pegvisomant and its place in the treatment journey for acromegaly patients
Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and Blueteq funding arrangements to homecare service provision
To find out more about ACRODAT, supporting your patients or to order starter kits
Discover how Blueteq fits within the Somavert prescribing pathway and the different types of homecare we offer
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020